

After entry of the amendments made herein, the claims pending in this application will read as follows.

16. (Amended) A method for treating or preventing Japanese cedar pollen allergy in a subject in need thereof, the method comprising:

(a) identifying an HLA class II molecule expressed by the subject;

(b) selecting an antigenic peptide derived from Japanese cedar pollen allergen Cry j 1 or Cry j 2, wherein the antigenic peptide binds to HLA class II molecule and wherein:

- C 45
- (1) when the HLA class II molecule identified in step (a) is DQA1*0102-DQB1*0602, the antigenic peptide is selected from the group consisting of SEQ ID NO: 1, 5, 7, 9, 10, 21, 23, and 142;
 - (2) when the HLA class II molecule identified in step (a) is DPA1*0101-DPB1*0501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 2, 8, and 15;
 - (3) when the HLA class II molecule identified in step (a) is DPA1*0101-DPB1*0201, the antigenic peptide is SEQ ID NO: 17;
 - (4) when the HLA class II molecule identified in step (a) is DPA1*0202-DPB1*0501, the antigenic peptide is SEQ ID NO: 22;
 - (5) when the HLA class II molecule identified in step (a) is DRB5*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 3, 4, 14, and 19;
 - (6) when the HLA class II molecule identified in step (a) is DRB1*0901, the antigenic peptide is selected from the group consisting of SEQ ID NO: 6, 7, 12, 16, and 20;
 - (7) when the HLA class II molecule identified in step (a) is DRB4*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 7, 12, and 18; and

- (8) when the HLA class II molecule identified in step (a) is DRB1*1501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 13 and 19; and
- (c) administering the selected antigenic peptide to the subject.

17. (Amended) A customized pharmaceutical composition for treating a subject suffering from a Japanese cedar pollen allergy, the composition comprising:

(a) an effective amount of an antigenic peptide derived from Japanese cedar pollen allergen Cry j 1 or Cry j 2, wherein the antigenic peptide binds to an HLA class II molecule expressed by the subject and wherein:

- (1) when the subject expresses the HLA class II molecule DQA1*0102-DQB1*0602, the antigenic peptide is selected from the group consisting of SEQ ID NO: 1, 5, 7, 9, 10, 21, 23, and 142;
- (2) when the subject expresses the HLA class II molecule DPA1*0101-DPB1*0501, the antigenic peptide is selected from the group consisting of SEQ ID NO: 2, 8, and 15;
- (3) when the subject expresses the HLA class II molecule DPA1*0101-DPB1*0201, the antigenic peptide is SEQ ID NO: 17;
- (4) when the subject expresses the HLA class II molecule DPA1*0202-DPB1*0501, the antigenic peptide is SEQ ID NO: 22;
- (5) when the subject expresses the HLA class II molecule DRB5*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 3, 4, 14, and 19;
- (6) when subject expresses the HLA class II molecule DRB1*0901, the antigenic peptide is selected from the group consisting of SEQ ID NO: 6, 7, 12, 16, and 20;
- (7) when the subject expresses the HLA class II molecule DRB4*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO: 7, 12, and 18; and

C45

Applicant: T. Sone et al.
Serial No.: 09/308,027
Filed: May 12, 1999
Page: 20

Attorney Docket No. 06501-031001

(8) when the subject expresses the HLA class II molecule DRB1*1501, the
antigenic peptide is selected from the group consisting of SEQ ID NO: 13
and 19; and

(b) a pharmaceutically acceptable diluent or carrier.

CAS
concl